依达拉奉防治冠脉介入术前后对比剂肾病的临床研究

目的：探讨依达拉奉在冠脉介入术前后对比剂肾病中的防治作用。方法：将150例行冠状动脉介入术诊断及治疗的患者随机分为依达拉奉组（75例）及对照组（75例）,在全部采用水化治疗基础上,依达拉奉组在冠脉介入术当日开始给予依达拉奉30mg稀释后30min滴完,1次/12h,连续5d。观察术前、术后血清肌酐（Scr）、内生肌酐清除率（Cer）,血β2-微球蛋白（β2-M）、丙二醛（MDA）的含量和超氧化物歧化酶（SOD）的活性改变情况。结果：术后第1d、3d、5d,两组Cer与术前相比明显下降,Scr、β2-M分别与术前比较均明显升高（P〈0.05）。组间比较,对照组Cer较依达拉奉组低,差异有统计学意义,而Scr、β2-M明显升高（P〈0.05）。术后第1d、3d、5d依达拉奉组MDA含量较对照组明显降低（P〈0.05）,而SOD活性显著增加（P〈0.05）。结论：冠脉介入术前后使用依达拉奉可能有助于减少对比剂肾病的发生,机制可能与清除氧自由基有关。

Clinical Efficacy of Edaravone on preventing contrast induced nephropathy in paticnts underwent coronary angiography

Objective ：To investigate the efficacy of edaravone on preventing contrast induced nephropathy （CIN）. Methods： 150 patients underwent coronary angiograpby were randomized to the edaravone prevention group and control group. 75 patients in experiment group were treated with edaravone 30rag on the basis of hydrated therapy ,edaravone was diluted and intravenous infusion to each patient in 30min ,once every. 12 hours for 5 days. Serum creatinine（Scr）, endogenous creatinine clearance rate（Cer）, Bloodβ2-microglobuliu（ β2- M）, malo ndiald ehyde （MDA）, super -oxide dismutase （SOD）before and after the procedure were compared between the groups. Results：After day 1,day 3 and day 5, two groups of Cer significantly decreased when compared with those of preoperation （P〈0.05）, and Scr,Ba-M, significantly increased （P〈0.05）,and those in edaravone prevention group were higher than those in control group （P〈0.05）. After day l,day 3 and day 5 ,the content of MDA were significantly decreased, and the activity of SOD were obviously increased in edaravone treatment group compared with control group when compared with those of preoperation （P〈0.05）. Conclusion ： Edaravone use before and after angiography can reduce the incidence of CIN, which might be involved in scavenging the oxygen free.